Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast

 Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials
       to be Presented at the 2013 San Antonio Breast Cancer Conference

Combined Safety and Efficacy Results with ThermoDox® plus Hyperthermia for
Recurrent Breast Cancer at the Chest Wall

PR Newswire

LAWRENCEVILLE, N.J., Sept. 9, 2013

LAWRENCEVILLE, N.J., Sept. 9, 2013 /PRNewswire/ --Celsion Corporation
(NASDAQ: CLSN), a leading oncology drug development company, today announced
the presentation of the combined clinical study results from the Company's
Phase I DIGNITY study and the Duke University sponsored Phase I trial of
ThermoDox® plus hyperthermia in Breast Cancer Recurrences at the Chest Wall
(BCRCW) at the 2013 San Antonio Breast Cancer Conference to be held on
December 10 to December 14, 2013. The poster, titled "Novel Targeted Therapy
for Breast Cancer Chest Wall Recurrence: Low Temperature Liposomal Doxorubicin
and Mild Local Hyperthermia " will be presented by Professor Hope S. Rugo, MD,
from the UCSF School of Medicine. A copy of the poster presentation will be
made available on the Company's website following Dr. Rugo's presentation.

The two Phase I studies enrolled patients that had failed previous standard
chemotherapy and radiation therapy and have recurrent breast cancer on their
chest wall. There are no effective treatments available for these chest wall
tumors. ThermoDox® in combination with mild hyperthermia was evaluated in
these patients in up to six cycles. The studies were designed to determine the
Maximum Tolerated Dose (MTD), evaluate safety and determine early effects of
ThermoDox® in combination with hyperthermia. Clinically meaningful responses
were reported in 14 of the 23 evaluable patients. Based on the results from
these two Phase I studies, Celsion is currently enrolling up to 40 patients in
an open label Phase 2 study. Enrollment is being conducted at 5 US sites.
Further information can be found on the Company's website and at
www.clinicaltrials.gov.

"The patients enrolled in both of these Phase I trials have failed previous
treatment regimens including chemotherapy and radiation therapy. The cancer
has now appeared on their chest wall and the patients are faced with limited
or no treatment options. Breast cancer recurrence at the chest wall is
difficult to treat and is characterized by disfigurement, pain and restriction
of movement," said Dr. Nicholas Borys, Celsion's Vice President and Chief
Medical Officer. "The data from these two Phase I studies provides strong
evidence of ThermoDox's broad potential clinical value across different
cancers, including the ability to provide a new tool against aggressive,
superficial tumors. We look forward to rapidly recruiting patients for the
Phase 2 portion of the DIGNITY Study."

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and
commercialization of innovative cancer drugs including tumor-targeting
treatments using focused heat energy in combination with heat-activated
liposomal drug technology. Celsion has research, license, or commercialization
agreements with leading institutions including the National Institutes of
Health, Duke University Medical Center, University of Hong Kong, the
University of Pisa, the UCLA Department of Medicine, the Kyungpook National
University Hospital, the Beijing Cancer Hospital and the University of Oxford.

For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials by others; possible acquisitions of other
technologies, assets or businesses; possible actions by customers, suppliers,
competitors, regulatory authorities; and other risks detailed from time to
time in the Company's periodic reports filed with the Securities and Exchange
Commission.

Investor Contact

Jeffrey W. Church
Senior Vice President and
Chief Financial Officer
(609) 482-2455

SOURCE Celsion Corporation

Website: http://www.celsion.com
 
Press spacebar to pause and continue. Press esc to stop.